

# MEDICATION ADHERENCE OF THROMBOPOIETIN RECEPTOR AGONISTS IN IMMUNE THROMBOCYTOPENIC PURPURA: IDENTIFYING BARRIERS, CHALLENGES AND SOLUTIONS THROUGH PATIENTS FEEDBACK

F.THEUILLON<sup>1</sup>, J.CHAMBORD<sup>1</sup>, I.RAYMOND<sup>1</sup>, F.XUEREB<sup>1</sup>, J-F.VIALLARD<sup>2</sup>, S.DJABAROUTI<sup>1</sup>

<sup>1</sup>BORDEAUX UNIVERSITY HOSPITAL, DEPARTMENT OF PHARMACY, BORDEAUX, FRANCE  
<sup>2</sup>BORDEAUX UNIVERSITY HOSPITAL, DEPARTMENT OF INTERNAL MEDICINE, BORDEAUX, FRANCE

## INTRODUCTION

Idiopathic thrombocytopenic Purpura (ITP) is an autoimmune disease leading to an abnormal decrease in the level of platelets in the blood (<100G/L)

Physiopathology: presence of anti-platelet autoantibodies

**Hospitalization** : 4,000 patients hospitalized in France per year for ITP

**Incidence** : between 5 and 10 per 100,000 inhabitants

Romiplostim and Eltrombopag have obtained marketing authorization in the following indication : chronic ITP in adults and non-splenectomized children as second-line treatment

Mechanism: Stimulation of TPO receptor which is a growth and differentiation factor in vivo of the megakaryotic lineage

**Romiplostim** : weekly subcutaneous injection

**Eltrombopag** : daily oral administration

## AIMS AND OBJECTIVES

Identify barriers to medication adherence through patients feedback in order to develop a targeted interview. The pharmaceutical interview (PI) intends to enhance medication adherence after conventional hospitalization at the treatment initiation.

## METHODS

Set up : A questionnaire to assess patients satisfaction and knowledge regarding their treatment and condition

Inclusion : Patient initiated with a TPO agonist (Romiplostim or Eltrombopag) between 2021 and 2024 in the internal medicine department of the Bordeaux CHU

Data collection :

- Calling patients'
- Requesting patients consent
- Questioning patients following the established questionnaire
- 10 minutes

## MATERIALS

Questionnaire SATMED-Q / 6 themes :

1. patient's treatment
2. potential adverse effects
3. perceived effectiveness of the medication
4. practical aspects of medication intake
5. medical follow-up
6. overall satisfaction



## RESULTS

N= 13 PATIENTS INCLUDED




9 MEN

4 WOMEN

AVERAGE AGE : 63 YEARS

RESULTS OF PATIENTS' RESPONSES TO THE QUESTIONNAIRE



## DISCUSSION

Nearly 80% of patients found the medication effective due to an increase in platelet counts

Nearly half felt they lacked information about the medication upon discharge and expressed difficulties with administration :


- **Romiplostim** : difficulty regarding subcutaneous injection
- **Eltrombopag** : unknown method of taking, restrictive taking times with lack of knowledge of the interaction with dairy products

## CONCLUSION

Objective for the futur :



- Organize a pharmaceutical interview when initiating treatment and follow-up interview may be scheduled remotely between 3 to 6 months



- Supplement the interview by a medication guide to clarify administration and adverse effects

